Nolpaza (pantoprazole) lyophilizate for solution 40 mg. №1

$18.00

Nolpaza is used in the treatment of gastroesophageal reflux disease, heartburn, sour regurgitation and pain when swallowing. In addition, the drug has proven its effectiveness in complex therapy in the eradication of Helicobacter pylori and gastric ulcer and intestinal ulcers caused by the intake of non-steroidal anti-inflammatory drugs. Nolpaza is indicated for the treatment of Zollinger-Ellison syndrome, as well as other pathological conditions that are associated with increased gastric secretion.

Category:

Description

Nolpaza composition
The active ingredient is pantoprazole sodium sesquihydrate 40 mg.

Release form
It is produced in the form of  lyophilisate for the preparation of a parenteral solution.

Pharmacological properties
It is an antiulcer drug. The drug acts by inhibiting the proton pump of H + / K + -ATPase. When active molecules enter the tubular lumen of parietal cells, where the medium is acidic, they are oxidized, transforming into an active form. In this form, they bind the SH-groups of the H + / K + -ATPase, blocking (irreversibly) this enzyme. This disrupts the formation of hydrochloric acid (HCl), which is the main component of gastric juice.

Indications
Nolpaza is used in the treatment of gastroesophageal reflux disease, heartburn, sour regurgitation and pain when swallowing. In addition, the drug has proven its effectiveness in complex therapy in the eradication of Helicobacter pylori and gastric ulcer and intestinal ulcers caused by the intake of non-steroidal anti-inflammatory drugs. Nolpaza is indicated for the treatment of Zollinger-Ellison syndrome, as well as other pathological conditions that are associated with increased gastric secretion.

Contraindications
Cannot be used in the treatment of patients who suffer from dyspeptic disorders of neurotic etiology. Also, its use is unacceptable in case of hypersensitivity to the components of the drug.
When prescribing the drug, it is necessary to exclude the likelihood of the presence of malignant neoplasms in the patient, since the treatment can blur the clinical picture of the disease, which will not allow a timely diagnosis.

Children
It is not used in pediatrics.

Application during pregnancy and lactation
The experience of using the drug in the therapy of nursing and pregnant women is limited, and therefore, if it is necessary to use the drug during these periods, the necessary precautions should be taken.
The drug in the form of a lyophilisate is not used in the therapy of nursing and pregnant women.

Method of application and dosage
The drug is used by adults as prescribed and under the direct supervision of a physician.
Intravenous use of the drug is recommended only if oral administration is not possible. There are data on the duration of intravenous treatment up to 7 days. Therefore, in case of clinical possibility, the transition from intravenous Nolpazia to oral.
Reflux esophagitis, duodenal ulcer, gastric ulcer.
The recommended dose is 40 mg of pantoprazole (1 vial) per day intravenously.
Treatment of Zollinger-Ellison syndrome and other hypersecretory pathological conditions.
For long-term treatment of Zollinger-Ellison syndrome and other hypersecretory pathological conditions, the recommended starting dose of Nolpaza is 80 mg per day. If necessary, the dose can be titrated, increasing or decreasing, depending on the secretion of acid in the stomach. Doses in excess of 80 mg per day should be divided into two administrations. A temporary increase in the dose of pantoprazole to more than 160 mg is possible, but the duration of use should be limited to the period necessary for adequate control of acid secretion.
If a rapid decrease in acidity is required, an initial dose of 2 x 80 mg is sufficient for most patients to reach the desired level (<10 mEq / h) within 1 hour.
Preparation for use.
The powder is dissolved in 10 ml of 0.9% sodium chloride solution added to the vial. The solution can be administered directly or after mixing with 100 ml of 0.9% sodium chloride solution or 5% glucose solution in plastic or glass vials.
After dilution, the chemical and physical stability of the drug is maintained for 12 hours at a temperature of 25 ° C. From a microbiological point of view, the diluted drug should be used immediately.
Nolpaza should not be prepared or mixed with solvents other than those mentioned above.
Intravenous administration of the drug should be carried out for 2-15 minutes.
The bottle is for single use only. Before use, it is necessary to visually check the drug in the vial (in particular for discoloration, the presence of sediment).
The diluted solution should have a clear yellowish color.

Overdose
Until recently, there were no cases of drug overdose.
When taking the drug in increased doses, the patient should flush the stomach and prescribe the intake of activated charcoal. In especially difficult cases, symptomatic therapy is recommended.

Side effects
When taking the drug, patients may complain of abdominal pain, stool disturbance, flatulence, dry mouth mucous membranes, nausea, vomiting, dizziness, visual impairment, peripheral edema and depression. In addition, patients with hypersensitivity to the drug may experience various allergic reactions, manifested by itching, skin rashes, hyperemia and anaphylactic shock.

Storage conditions and periods
Nolpaza should be stored in places that are out of the reach of children and protected from light. The duration of storage of the lyophilisate for the preparation of the solution is 3 years.